Literature DB >> 8438565

Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle.

D Blanc1, C Patience, T F Schulz, R Weiss, B Spire.   

Abstract

The vif gene of HIV-1 has previously been claimed to be essential for the ability of cell-free virus preparations to infect cells. Here we report that the CEM T-cell-line, stably transfected with and expressing vif, supports the replication of vif- HIV-1 viruses to the same extent as wild-type HIV1. Cell entry and early replication stages are the same for vif- and vif+ HIV-1 passaged in CEM, as measured both by a PCR-based cell entry assay and by fusogenic potential. These findings indicate that vif does not affect viral infectivity on CEM cells, but seems to act at a later stage of virus replication/maturation. We also show that the VIF proteins of two different HIV-1 strains can transcomplement different vif- HIV-1 mutants.

Entities:  

Mesh:

Year:  1993        PMID: 8438565     DOI: 10.1006/viro.1993.1114

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.

Authors:  M Bouyac; F Rey; M Nascimbeni; M Courcoul; J Sire; D Blanc; F Clavel; R Vigne; B Spire
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.

Authors:  P D'Aloja; E Olivetta; R Bona; F Nappi; D Pedacchia; K Pugliese; G Ferrari; P Verani; M Federico
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Comparison of the replication and persistence of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA or HCCH domains in macaques.

Authors:  Kimberly Schmitt; M Sarah Hill; Zhenqian Liu; Autumn Ruiz; Nathan Culley; David M Pinson; Edward B Stephens
Journal:  Virology       Date:  2010-09-01       Impact factor: 3.616

5.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.

Authors:  M Bouyac; M Courcoul; G Bertoia; Y Baudat; D Gabuzda; D Blanc; N Chazal; P Boulanger; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

Authors:  X Y Ma; P Sova; W Chao; D J Volsky
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.